31406-95-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-BROMOETHOXY)PHENOL is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medications.
Used in Agrochemical Industry:
4-(2-BROMOETHOXY)PHENOL is used as an intermediate in the synthesis of agrochemicals, playing a role in the creation of products that protect crops and enhance agricultural productivity.
Used in Specialty Chemicals Industry:
4-(2-BROMOETHOXY)PHENOL is used as a building block for the creation of other specialty chemicals, contributing to the development of unique and innovative chemical products.

InChI:InChI=1/C8H9BrO2/c9-5-6-11-8-3-1-7(10)2-4-8/h1-4,10H,5-6H2

Upstream product

• 589-10-6 phenoxyethyl bromide 
• 3351-59-5 2-(4-benzyloxyphenoxy)ethyl bromide 
• 106-93-4 ethylene dibromide 
• 123-31-9 hydroquinone 

Downstream Products

• 109963-50-0 butyl-[2-(4-hydroxy-phenoxy)-ethyl]-dimethyl-ammonium; bromide 
• 108856-98-0 N-benzyl-2-(p-hydroxyphenoxy)ethylamine 
• 60573-92-4 2-(4-Hydroxy-phenoxy)-aethylhydrazin 
• 841200-56-4 1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-4-carboxylic acid ethyl ester 
• 911626-94-3 2-{4-[(2-phenyl-ethyl)oxy]phenyl}ethyl bromide 
• 107332-63-8 N-benzyl-2-(4-hydroxyphenoxy)ethylamine hydrochloride 
• 911627-09-3 C₁₇H₂₄N₂O₃ 
• 1190927-32-2 2-[4-(2-bromoethoxy)phenoxy][1,3]thiazolo[4,5-b]pyridine 

Relevant academic research and scientific papers

Chalcogen Bonding Macrocycles and [2]Rotaxanes for Anion Recognition

Electron-deficient heavy chalcogen atoms contain Lewis acidic σ-holes which are able to form attractive supramolecular interactions, known as chalcogen bonding (ChB), with Lewis bases. However, their potential in solution-phase anion binding applications is only just beginning to be realized in simple acyclic systems. Herein, we explore the 5-(methylchalcogeno)-1,2,3-triazole (chalcogen = Se, Te) motif as a novel ChB donor for anion binding. Other than being chemically robust enough to be incorporated into macrocyclic structures, thereby significantly expanding the scope and complexity of ChB host systems, we also demonstrate, by 1H NMR and DFT calculations, that the chalcogen atoms oriented within the macrocycle cavity are able to chelate copper(I) endotopically. Exploiting this property, the first examples of mechanically interlocked [2]rotaxanes containing ChB-donor groups are prepared via an active metal template strategy. Solution-phase 1H NMR and molecular modeling studies provide compelling evidence for the dominant influence of ChB in anion binding by these interlocked host systems. In addition, unprecedented charge-assisted ChB-mediated anion binding was also studied in aqueous solvent mixtures, which revealed considerable differences in anion recognition behavior in comparison with chalcogen-free host analogues. Moreover, DFT calculations and molecular dynamics simulations in aqueous solvent mixtures indicate that the selectivity is determined by the different hydrophilic characters of the anions allied to the hydration of the binding units in the presence of the anions. Exploiting the NMR-active nuclei of the ChB-donor chalcogen atoms, heteronuclear 77Se and 125Te NMR were used to directly study how anion recognition influences the local electronic environment of the chalcogen atoms in the mechanically bonded rotaxane binding sites in organic and aqueous solvent mixtures.

Synthetic method 4 - alkoxyphenol compounds

The invention discloses a synthetic method of 4 - alkoxyphenol compounds, and belongs to the field of organic chemical synthesis. The method is as follows: An aryl alkyl ether compound is added to the sealing tube. The catalyst dimerization acetic acid rhodium and the oxidizing agent iodobenzene diethyl ester are added, a solvent trifluoroacetic anhydride is added, and the 4 -alkoxyphenol compound is prepared by heating reaction. To the invention, high regioselectivity direct hydroxylation of the aryl alkyl ether compound is realized, the application range of the substrate is wide, the yield is high, the activity after amplification reaction does not significantly decay, and higher yield is still obtained. The utility model has good practicability and industrial application prospect.

Para -Selective hydroxylation of alkyl aryl ethers

para-Selective hydroxylation of alkyl aryl ethers is established, which proceeds with a ruthenium(ii) catalyst, hypervalent iodine(iii) and trifluoroacetic anhydride via a radical mechanism. This protocol tolerates a wide scope of substrates and provides a facile and efficient method for preparing clinical drugs monobenzone and pramocaine on a gram scale.

Synthesis, antimicrobial evaluation, and in silico studies of quinoline—1H-1,2,3-triazole molecular hybrids

Abstract: Antimicrobial resistance has become a significant threat to global public health, thus precipitating an exigent need for new drugs with improved therapeutic efficacy. In this regard, molecular hybridization is deemed as a viable strategy to afford multi-target-based drug candidates. Herein, we report a library of quinoline—1H-1,2,3-triazole molecular hybrids synthesized via copper(I)-catalyzed azide-alkyne [3 + 2] dipolar cycloaddition reaction (CuAAC). Antimicrobial evaluation identified compound 16 as the most active hybrid in the library with a broad-spectrum antibacterial activity at an MIC80 value of 75.39?μM against methicillin-resistant S. aureus, E. coli, A. baumannii, and multidrug-resistant K. pneumoniae. The compound also showed interesting antifungal profile against C. albicans and C. neoformans at an MIC80 value of 37.69 and 2.36?μM, respectively, superior to fluconazole. In vitro toxicity profiling revealed non-hemolytic activity against human red blood cells (hRBC) but partial cytotoxicity to human embryonic kidney cells (HEK293). Additionally, in silico studies predicted excellent drug-like properties and the importance of triazole ring in stabilizing the complexation with target proteins. Overall, these results present compound 16 as a promising scaffold on which other molecules can be modeled to deliver new antimicrobial agents with improved potency. Graphic abstract: [Figure not available: see fulltext.].

Synthesis and Investigation of S-Substituted 2-Mercaptobenzoimidazoles as Inhibitors of Hedgehog Signaling

Due to the arising resistance of common drugs targeting the Hedgehog signaling pathway, the identification of new compound classes with inhibitory effect is urgently needed. We were able to identify S-alkylated 2-mercaptobenzoimidazoles as a new compound

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

This study explores the possible use of reactive oxygen-activated DNA modifying agents against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progenitor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this novel type of agent may be useful against AML.

ROS-Activated Compounds as Selective Anti-Cancer Therapeutics

Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.

LTA4H modulators and uses thereof

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

Identification of a potent, selective, and orally active leukotriene A 4 hydrolase inhibitor with anti-inflammatory activity

LTA4H is a ubiquitously distributed 69 kDa zinc-containing cytosolic enzyme with both hydrolase and aminopeptidase activity. As a hydrolase, LTA4H stereospecifically catalyzes the transformation of the unstable epoxide LTA4 to the diol LTB4, a potent chemoattractant and activator of neutrophils and a chemoattractant of eosinophils, macrophages, mast cells, and T cells. Inhibiting the formation of LTB4 is expected to be beneficial in the treatment of inflammatory diseases such as inflammatory bowel disease (IBD), asthma, and atherosclerosis. We developed a pharmacophore model using a known inhibitor manually docked into the active site of LTA4H to identify a subset of compounds for screening. From this work we identified a series of benzoxazole, benzthiazole, and benzimidazole inhibitors. SAR studies resulted in the identification of several potent inhibitors with an appropriate cross-reactivity profile and excellent PK/PD properties. Our efforts focused on further profiling JNJ 27265732, which showed encouraging efficacy in a disease model relevant to IBD.

Phenyl and pyridyl LTA4H modulators

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and inflammatory conditions.